To study the impact of drug licensing on its sales, and to provide a reference for drug development and corporation between pharma. METHODS: Based on the variables "license station", "co-development or co-marketing", "licensor in accord with key marketing company or not" and "time for drug licensing" which reflected drug licensing and sales, with SPSS statistical software, T-test and Q-test of drug licensing and the sales of drugs were carried out on the 151 sample drugs collected in IMS Health. RESULTS & CONCLUSIONS: Drugs with licensing activities have higher sales than those without licensing. There is no significant difference between co-development and co-marketing for the drugs, Licensor hold the key marketing right helps improve sales of drugs. The optimum time for drug licensing is phase Ⅲ.
corresponding to the three indicators of "licensing station", "co-development or co-marketing", "licensor in accord with key marketing company or not" is conducted by SPSS22.00.Then, one-way ANOVA is conducted for the average sales corresponding to the classification variable of "licensing time" to determine the significance of the difference between groups, If P<0.05, LSD method is used to compare the average number of samples in pairs, i.e., Q test, to determine whether the impact of different intervention time on sales was significant. Following information can be found from table 2, F value 4.27, significance P=0.041<0.05, and variance heterogeneity. The second row of data was selected as the result of the analysis, t value 2.815, significance P=0.006<0.05, indicating that at the significance level of 0.05, the two groups' average sales was significantly different, and the sales of drugs with licensing activities have higher sales than those without licensing.
Empirical results and analysis

Whether license station can affect drug sales
Influence of co-marketing/co-development on sales
From table 3, we can find that there are 43 drugs had only signed co-marketing agreements, whose average sale is $1.63 billion. And 79 drugs had signed co-development agreements, whose average sale is $2.05 billion. According to table 4, the F value is 0.758, the significance P=0.386>0.05, the homogeneity of variance. The first row of data was selected to analysis. T value is -1.315, significance P=0.191>0.05, which indicate that there was no significant difference in average sales between the two groups at significance level of 0.05. Drug sales under co-development agreements are slightly higher than those under co-marketing, but the results of two models are not significant. 
Influence of time for drug licensing on sales
As can be seen from table 6, F value 2.81, significance P=0.096>0.05, homogeneity of variance. The first row of data was selected to analysis, T value 2.517, significance P=0.013<0.05, which indicate the average sales of the two groups of samples was significantly different at the significance level of 0.05. For the original researchers, the sales of drugs with the main marketing right is obviously higher than those without the marketing right. As shown in table 9, the significant degree P between the fourth groups and other groups is always less than 0.05, indicating that at the significant level of 0.05, the differences between the fourth groups and the other groups were significant. The sales licensed in the stage III stage were significantly higher than those of the other stages (see Fig. 1 ). 
Discussion and conclusions
Licensing is a common cooperative activity in the modern pharmaceutical industry, especially in today's emerging environment of biotechnology companies and CROs. Large pharmaceutical groups introduce (License-in) biotechnology companies to cooperate in the development of certain products, and authorize (license-out) compound patents to CRO companies for clinical trials, new dosage forms, new indications development, or grant production rights to generic drug manufacturers, and marketing rights to pharmaceutical Trading companies [2] . This paper discusses the influence of licensing on sales from the perspectives of the authorized person/transferee, R&D/marketing, original researcher/marketer, and licensing time. The following conclusions are drawn:
(1) By authorizing and integrating external resources, the balance of cost, risk and benefit can be achieved, and the sales volume of drugs can be effectively increased. This is in line with the new idea of openly innovation of modern medicine, that is, enterprises use the ideas and knowledge of external innovators to gain innovation in the process of innovation [5] . At the same time, it also accord with the new strategy of modern enterprise market development, that is, enterprises use local enterprises to achieve market share in the process of development.
(2) There is no obvious difference between the two licensing modes of co-development or co-marketing on sales, thus pharmaceutical companies should make decisions to choose the mode according to their actual conditions. Licensing at the development stage can reduce the risk of R&D, as well as improve the performance of drugs in terms of safety/efficacy and quality control. Co-marketing, on the other hand, can rapidly expand marketing channels, improve market penetration and build brand image.
(3) Original researchers need master the main marketing rights. Technology, commerce and law are the three major factors influencing drug sales: high technology content, mature commercial development and the market monopoly right brought by patent protection, which are the key conditions of the big-selling medicines [6] . The original researchers have both core technologies and corresponding patents, if they can also grasp the right to commercial development or play a leading role in co-marketing, it will certainly promote the sales performance of drugs.
(4) Licensing at the stage of clinical Ⅲ will benefit enterprises more. Most development licensing agreement occurred early, namely between pre-clinical trials and clinical Ⅱ [2] .The reason is most pharmaceutical companies sign agreement in lower prices for higher uncertainty in early time [7] . But in this paper, the results show that the drugs in the clinical Ⅲ issue authorization eventually achieve maximum output. The reason is that the drug technology at this stage is relatively mature, the uncertainty and risks are reduced, and the best game point can be found in the cooperation between the two sides, which is of more positive significance to promote drug sales.
For the first time, continuous sales data mean is adopted in this paper, corresponding to different licensing variables, and empirical analysis is carried out to verify the influence of licensing on sales. In fact, there are many factors influencing sales, and licensing is only one of them. This paper is not intended to explain the clear causal and quantitative relationship between licensing mode and sales, nor does it expect to predict sales through licensing data. This analysis is based on the single data of IMS Health, and there are some shortcomings :(1) The sample size is relatively small due to the need to take into account both the R&D information and the five-years sales data, and most of them are top-ranking drugs;
The rising R&D cost and the decreasing innovation yield year by year make pharmaceutical development enterprises to adopt new strategies and business models [8] . Enterprises can get a better market performance through technology transfer, market cooperation, and M&A activities. Thus, reasonable licensing is undoubtedly an effective strategy.
